FDA Accepts sNDA for Jardiance in Children 10 to 17 with Diabetes
If approved, Jardiance would be the first SGLT2 inhibitor indicated for this population. A decision is expected in the second quarter of 2023.
The FDA has accepted a supplemental new drug application (sNDA) for Jardiance (empagliflozin) to lower blood sugar in children 10 years and older with type 2 diabetes. An FDA decision is expected in the second quarter of 2023. Developed by Boehringer Ingelheim and Eli Lilly, Jardiance is approved for several indications, including treating adults with type 2 diabetes, to reduce the risk of cardiovascular disease in adults with diabetes and to reduce the risk of heart failure.
The current list price for a month supply of Jardiance is $570.48, but patients can access a copay card for $10 per month.
Mohamed Eid, M.D.
“There are clear unmet needs for young people living with type 2 diabetes, which has nearly doubled in prevalence in people aged 10-19 over the past two decades,” Mohamed Eid, M.D., vice president, clinical development & medical affairs, cardio-renal-metabolism & respiratory medicine at Boehringer Ingelheim Pharmaceuticals, said in a press release.
The sNDA is based on the results from the DINAMO phase 3 trial, which enrolled 158 patients between 10 and 17 years of age. They were randomized to Jardiance, Tradjenta (linagliptin) or placebo. The study found that Jardiance was associated with a statistically significant reduction in the primary endpoint of change from baseline in A1c at 26 weeks compared with placebo in participants aged 10 to 17 years with type 2 diabetes. Jardiance 10 mg and 25 mg pooled doses reduced A1c by 0.84% compared with placebo at week 26. Reduction in A1c in participants treated with Tradjenta was not statistically significant when compared with placebo. Results were presented during the International Diabetes Federation World Diabetes Congress 2022.
Overall, the safety data was consistent with the previously known safety profile of Jardiance.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
